Profile
Christopher G.
Tate is the founder of Heptares Therapeutics Ltd.
founded in 2007.
He worked as a Principal at the University of Cambridge and the MRC Laboratory of Molecular Biology.
Dr. Tate earned a doctorate degree from the University of Bristol in 1989.
Former positions of Christopher G. Tate
| Companies | Position | End |
|---|---|---|
| University of Cambridge | Corporate Officer/Principal | - |
MRC Laboratory of Molecular Biology
 MRC Laboratory of Molecular Biology Miscellaneous Commercial ServicesCommercial Services MRC Laboratory of Molecular Biology provides biological research and development services. it also offers methods for determining the three-dimensional structures of proteins and other macromolecules, the sequencing of DNA and the development of monoclonal antibodies. The company was founded by Max Ferdinand Perutz in 1962 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Founder | - |
Training of Christopher G. Tate
| University of Bristol | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
MRC Laboratory of Molecular Biology
MRC Laboratory of Molecular Biology Miscellaneous Commercial ServicesCommercial Services MRC Laboratory of Molecular Biology provides biological research and development services. it also offers methods for determining the three-dimensional structures of proteins and other macromolecules, the sequencing of DNA and the development of monoclonal antibodies. The company was founded by Max Ferdinand Perutz in 1962 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Christopher G. Tate
